Small Molecule MP-4222 Potently Antagonizes GRPR, Inhibiting Histamine-Independent Itch in Mice
Background
Persistent pruritus (itch) significantly impairs quality of life, with many syndromes lacking effective treatments. A critical gap exists in therapies for histamine-independent itch, which current antihistamines cannot address. The gastrin-releasing peptide receptor (GRPR) has been identified as playing a pivotal role in mediating this specific type of itch signaling. Targeting GRPR offers a promising avenue for developing novel antipruritic agents, especially given its established role in various physiological processes and its potential as a therapeutic target.
Study Design
Researchers initiated a systematic structure-activity relationship (SAR) study, starting with the known small-molecule GRPR antagonist PD 176,252. This iterative process involved synthesizing and evaluating numerous analogs to enhance binding affinity and selectivity. The most promising compounds were then tested for their ability to inhibit itch behavior in an in vivo model. Specifically, Compound 45 (MP-4222) was evaluated in a chloroquine (CQ)-induced acute itch mouse model to assess its efficacy in reducing scratching behavior. Computational docking outcomes were also reconciled with a recently reported GRPR-PD176252 cryo-EM structure to guide further modifications.
Results
The SAR studies successfully identified novel GRPR antagonists, with some exhibiting an impressive 11-fold increase in binding affinity compared to the starting compound, PD 176,252. Among these, Compound 45 (MP-4222) stood out, demonstrating a four-fold increased binding affinity to GRPR while maintaining equal selectivity over the neuromedin B receptor (NMBR). This enhanced affinity translated into significant in vivo activity. > MP-4222 significantly inhibited itch behavior in the chloroquine (CQ)-induced acute itch mouse model, validating GRPR antagonism as an effective strategy for histamine-independent pruritus. Furthermore, the study reconciled discrepancies between in vitro data and computational docking using the GRPR-PD176252 cryo-EM structure, providing structural insights. The research also suggested several potential modifications for further potency improvement and identified functional groups suitable for radiolabeling, opening avenues for GRPR imaging.
Key Findings
- Systematic SAR studies led to novel GRPR antagonists with up to an 11-fold increase in binding affinity compared to PD 176,252.
- Compound MP-4222 (Compound 45) demonstrated a four-fold increased binding affinity to
GRPR. - MP-4222 maintained equal selectivity over the
neuromedin B receptor (NMBR). - MP-4222 significantly inhibited itch behavior in the
chloroquine (CQ)-induced acute itch mouse model.
Why It Matters
The discovery of MP-4222 offers a significant step forward for individuals suffering from histamine-independent pruritus, a condition with limited treatment options. This compound represents a promising lead for developing a new class of antipruritic drugs that target GRPR, potentially offering relief where antihistamines fail. The detailed SAR and structural insights provide a robust foundation for further optimization, accelerating the path towards clinical translation. Moreover, the identification of functional groups for radiolabeling suggests future applications in diagnostic imaging for conditions where GRPR is implicated, such as certain cancers, or for precisely tracking drug distribution in itch pathways. This work could lead to more targeted and effective therapies for chronic itch.
grpr antagonist
pruritus
itch
small molecule
preclinical-animal
drug discovery